AMLX FY 2024 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$87M-77.1% YoY

Gross Profit

$45M51.8% margin

Operating Income

-$315M-360.2% margin

Net Income

-$302M-345.4% margin

EPS (Diluted)

$-4.43

Cash Flow

Operating Cash Flow

-$168M

Free Cash Flow

-$168M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$194M

Total Liabilities

$29M

Stockholders' Equity

$165M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$381M	-77.1%
Gross Profit	$45M	$355M	-87.3%
Operating Income	-$315M	$39M	-911.1%
Net Income	-$302M	$49M	-712.4%